IMMEDIATE Therapeutics is a clinical stage biotech company focused on Cardiovascular diseases and dedicated to developing safe and effective therapeutic solutions to minimize heart muscle damage in Acute Coronary Syndromes (ACS) leading to Cardiac Arrest, the most common cause of death and morbidity across the world.IMT-358: First-in-class product providing metabolic protection to minimize cardiac damage and instability during acute coronary syndromes (ACS)Phase 2 Completed: Trial (n=871) showed treatment associated reduction in infarct size by 80%; and reduced odds of cardiac arrest/mortality by over 50% Planned Phase 3 Study: Risk Mitigated 3 Year Study in the US and EU with 1600 patients set to begin Q4 2022Single Pivotal Phase 3 under FDA’s Special Protocol AssessmentPotential Accelerated Approval (900 patients – 1 year)Granted FDA Breakthrough DesignationIMT-358 designated as a Biologic, so eligible for BLA with 12-year market protection at end of trialStrong IP position with currently filed and additional new claims including formulation and final drug productBlockbuster potential with global market estimates of $25B by 2035; first mover advantageContributions from Baxter for clinical supply with potential long-term interest for ACS and additional indicationsStrong leadership and advisory team of world-renowned emergency cardiology experts & biotech executivesRaised over $40M in non-dilutive funding – Now seeking $60M in first ever equity funding to secure global approval of first indication in ACS with potential for additional indications in the future

Developing, Communicating, Executing, and Sustaining Corporate Strategic Initiatives to drive HBM’s Overall Success.• Developed the short- and long-term strategy for HBM including project prioritization and investment focus to streamline company deliverables and meet investor expectations for optimized burn rate vs. major milestone achievements. • Lead a complex four party deal with UU, EMC and AbbVie to out-licence a potent anti-SARS-CoV2 antibody to treat patients with COVID-19• Lead the transformation of HBM from a platform focused company to a product and portfolio company to increase the company’s value in time for an IPO.• Supported B+ and C round VC funding of close to $200M and successful completion of IPO in the HK exchange raising over $221M - all in the same year. • Heading alliance management to discover and develop next-gen therapeutics in the field of IO and Immunology. Evaluating new approached including AI to go beyond traditional drug discovery and development and commercialization efforts.• Leading efforts to prepare for another round of fund raising as well as IPO, including building value creation model, managing internal and external stakeholder communication and being the face of HBM in front of the external community globally.• Set up a growing footprint and established smooth operations for commercial and R&D activities in the US – leading a team of 12, from lab bench to BD activities and investor engagement. Face of company with FDA, KOLs, alliances and investors.

Delivering Operational Effectiveness and Global Launch Excellence for a multi-indication asset. • Leading cross functional product teams to develop the launch strategy to achieve brand revenue for overall Dupixent Franchise and it’s multiple and diversified TA’s (Dermatology and Respiratory). • Leading launch excellence in partnership with global affiliates to ensure launch readiness and execution to strategy. Ensured successful design, resourcing, execution and tracking of all pre-launch disease state and brand development activities. Built detailed plans defining sequence of activities and Go-to-Market Strategy, including a “launch tracker” to manage all pre-launch planning and execution through approval and market launch.• Develop and execute launch governance, business processes, pre- and post-launch KPIs to evaluate business opportunities, track and assess against predefined launch success criteria and implement course correction, if needed.• Defining and driving business goals for the product by delivering high quality strategic and brand plans for the business across several key function. Generate all pre and post-launch forecasts and valuations in conjunction with affiliates and forecasting team. Establish and deliver on P&L targets globally.• Contribute to cross-franchise strategy projects requiring input from and/or have implications on commercial strategy, including communication to investors. • Manage the global marketing budget with discipline including LCM strategy and navigate organization to secure resources and commitment for key functional activities important for the success of the brand. • Develop priorities with the cross-functional team to help develop SMART goals for individual members of the franchise. Help develop rules of engagement across alliances across portfolio.

Delivering Operational Excellence and Business Development EvaluationsUnit Management Office: Accountable for budget forecasts, tracking and reporting alongside long range plans, business and budget reviews.• Managed internal and external resources to warrant quality project delivery within cost and time constraints. Ensured consistent project management practices across functions and product teams to support strategic decision making. Implemented tools to produce an integrated portfolio view of activity and resource information required to make optimal product, portfolio, and capacity planning decisions. • Accountable for governance, contracts, compliance, communication, training and development of people.Business Development: Played a key role in corporate strategic planning process and meeting the development objectives towards optimizing the I&I portfolio via creation of transformative partnerships. • Identified, evaluated and championed new collaboration opportunities through in-licensing and M&A activities including assessment of in-licensing needs, asset identification, and collaboration structuring. • Responsible for initial presentations, clinical development plans, target product profiles, trial costs, due diligence, capabilities presentations to support deal negotiations.

Global Project Manager: Delivered on critical internal and external milestones for key projects including Dupilumab (late stage multi-indications) & Synvisc-One (marketed). Managed internal and external stakeholders through engaging communication to warrant alignment on project strategy and execution plans of ongoing clinical development plans. • Ensured translation of project strategy into a robust and realistic operational plan, working closely with the Global Project Head and all relevant functions, leading to successful registration and commercialization of high value assets. Developed scenario alternatives, identified risks and mitigation plans for several aspects including clinical development, regulatory and market access, and managed variances in timings, budget and project quality. Prepared teams and presentations for Sanofi and joint governance meetings.• Contributed to strategy of project and sub-projects per indication, aligned functional plans across indications, prepared fully-integrated program timelines to guarantee execution. Monitored sub-teams to drive execution of plans, challenged and enabled functional commitment to perform activities and deliver against an optimized project plan.

Developing and implementing R&D strategy for Sanofi’s Asia Pacific Therapeutic Strategy Unit.Strategic Planning: Led development and implementation of Sanofi’s short and long-term R&D Strategy in Asia Pacific including research, clinical development and in-licensing opportunities.• Developed comprehensive understanding of the macro and micro-parameters contributing towards designing a pragmatic strategy and operational efficiencies to bring Sanofi’s portfolio to the Asia Pacific. • Mapped the science policy challenges and developed strategy for Sanofi’s R&D operations in the region to minimize the impact on Sanofi’s freedom to operate across the AP region.R&D Transversal Projects: Participated in several high impact initiatives working transversally across different functions including focus on Global Emerging Markets. • Broader and transversal involvement in issues affecting operational aspects of R&D activities including HR, finance, portfolio management, etc.• Attaché to Head of AP R&D –Responsible for internal and external stakeholder management for the unit, advice on key strategic initiatives and people management, set and follow up priorities for the group, represent on different occasions.

Deallus Consulting improves your strategy by developing, testing and refining the key market assumptions that underpin it. Focus on the Life Sciences industry with efficient and comprehensive research and rigorous analysis. Delivering Competitive Intelligence and Strategy Consulting services to corporate decision makers.• Strategic Planning: Led multiple teams to provide clients with key intelligence support on competitor’s clinical developments and underlying strategies in the field of Ophthalmology, Onco, CV and Metabolic diseases, Neurological and Immunological disorders, Companion Diagnostics and Medical devices. Simultaneously managed multiple projects, meeting several competing deadlines while providing strong direction and support to project team members to achieve project goal(s).• Provided competitive intelligence and presented actionable recommendations based on primary and secondary research collected from different sources. Used scattered pieces of information to build holistic predictive landscapes in order to support key stakeholders thinking and influence opinions to align with competitor actions and market demands in order to mitigate future risks and surprises. • Developed global market access and launch strategies for mid and big pharma to launch high profile products in US and global markets using intelligence and war game approaches. Portfolio Analytics: Analyzed portfolios and presented comprehensive recommendations to large and midsize pharma by comparing R&D and commercial attributes alongside historic trends and evolving PESTEL scenarios• Developed multiple strategies and pragmatic recommendations for both early and late stage compounds in clinical development with client R&D and commercial teams to maximize resources and control costs.• Facilitated and participated in scenario planning workshops and war-games with large client teams to explore future scenarios in order to plan and prepare, if such scenarios were to come true.

InnoStrats Consulting is a boutique life science consulting firm primarily focusing on Innovation Management and Strategy. The needs of life science companies are unique, requiring a fundamental understanding of the medical and scientific issues associated with therapeutics and diagnostics. In order to address our clients’ needs, InnoStrats brings both breadth and depth of life science knowledge combined with seasoned consultants specializing in new product planning and commercialization strategy as well as portfolio management and diversification to a variety of life science markets. This mix of capabilities positions our firm to consistently deliver high quality advice and pragmatic recommendations backed by data–driven market research for executives and investors in our areas of focus, which include:• Pharmaceutical• Biotechnology• Medical Devices• Contract Research• Diagnostics• Drug DiscoveryProjects:• Reviewed existing new product introduction (NPI) process, market analysis, competitor evaluation and stakeholder management. Provide recommendations to improve process to strategically align with divisional and company strategy resulting in 50% increase in NPI, 30% reduction in time to market and 9% increase in net profits. • Built and developed long-term senior level contacts and strong relationships to help clients obtain funding and resolve current and future issues facing pharmaceutical and life-sciences R&D. Formulated pragmatic growth strategy for their therapeutic drug portfolio based on scenario planning for the future.• Provided shareholders and investors in-depth analysis, critique and recommendations on a big pharma’s sustainability efforts by comparing to government regulations and industry standards for 2008-09. The project ensued significant policy changes within the company to become more environmentally and financially sustainable.

Reuters Insight is an independent research consultancy that provides customized solutions to decision makers and corporate leaders. Drawing on primary resources, our Community of Experts and our research teams in Asia, Europe and the Americas, we deliver relevant and meaningful information that drives better decisions.

Guidepoint Global is a primary research firm that provides investors and business decision-makers with on-demand access to its worldwide network of industry experts. Established in 2003 as Clinical Advisors, we changed our name in November 2007 to better communicate the breadth of our expertise and services. Our clients include some of the world’s leading private equity firms, mutual funds, hedge funds and strategy consultancies. Through phone consultations, face-to-face meetings, surveys and proprietary data products, we provide our clients with the customized information solutions they need to make informed decisions.• Identified complex issues and provided tailored analysis of problems by working with client’s executives and floor teams. Presented insightful conclusions and viable recommendations based on the company’s strategy and competitive strategic analysis of existing market conditions resulting in increased profitability (average of 20%) and increased ROI for all stakeholders. • Formulated and presented cost-benefit analysis for procurement including spend analysis, supplier evaluation, strategic sourcing, outsourcing/off-shoring advice, product portfolio, pricing and market access. • Initiated program to enhance personal experience, development and training of staff and students by implementing weekly meetings, presentations and feedback sessions.

• As project manager, coordinated strategic project activities with various departments including: design and planning, R&D expenditure, procurement and operations. This resulted in the smooth transition of projects through various development phases, while controlling & regulating priorities. • Led a team of 15 multicultural researchers to perform quality research and meet deadlines. Designed and implemented multiple innovative research ideas and project proposals. Drafted future projects based on results, targeted towards understanding and developing therapeutics for neurodegenerative diseases.• Presented research findings at international conferences. Mentored graduate and undergraduate students.